Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. / Prasad, Femin; De, Riddhita; Korann, Vittal; Chintoh, Araba F.; Remington, Gary; Ebdrup, Bjørn H.; Siskind, Dan; Knop, Filip Krag; Vilsbøll, Tina; Fink-Jensen, Anders; Hahn, Margaret K.; Agarwal, Sri Mahavir.
I: Therapeutic Advances in Psychopharmacology, Bind 13, 20451253231165169, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series
AU - Prasad, Femin
AU - De, Riddhita
AU - Korann, Vittal
AU - Chintoh, Araba F.
AU - Remington, Gary
AU - Ebdrup, Bjørn H.
AU - Siskind, Dan
AU - Knop, Filip Krag
AU - Vilsbøll, Tina
AU - Fink-Jensen, Anders
AU - Hahn, Margaret K.
AU - Agarwal, Sri Mahavir
PY - 2023
Y1 - 2023
N2 - Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (
AB - Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in the management of obesity in the general population, with preliminary evidence supporting efficacy in AAWG. Semaglutide is a weekly injectable GLP-1RA which received recent approval for obesity management and noted superiority over other GLP-1RAs. This study explored the efficacy and tolerability of semaglutide in AAWG among individuals with severe mental illness. A retrospective chart review of patients treated with semaglutide in the Metabolic Clinic at the Center for Addiction and Mental Health (CAMH) between 2019 and 2021 was conducted. Patients failing a trial of metformin (
KW - antipsychotics
KW - metformin
KW - obesity
KW - semaglutide
KW - severe mental illness
KW - ONCE-WEEKLY SEMAGLUTIDE
KW - PHASE 3A
KW - OPEN-LABEL
KW - DOUBLE-BLIND
KW - ADD-ON
KW - JAPANESE PATIENTS
KW - DAILY SITAGLIPTIN
KW - ORAL SEMAGLUTIDE
KW - DIABETES CARE
KW - DOUBLE-DUMMY
U2 - 10.1177/20451253231165169
DO - 10.1177/20451253231165169
M3 - Journal article
C2 - 37113745
VL - 13
JO - Therapeutic Advances in Psychopharmacology
JF - Therapeutic Advances in Psychopharmacology
SN - 2045-1253
M1 - 20451253231165169
ER -
ID: 347979678